Published in J Neuroinflammation on January 03, 2013
Quantification of gait parameters in freely walking rodents. BMC Biol (2015) 1.44
Phenotypic Identification of Spinal Cord-Infiltrating CD4(+) T Lymphocytes in a Murine Model of Neuropathic Pain. J Pain Relief (2014) 0.97
Slack sodium-activated potassium channel membrane expression requires p38 mitogen-activated protein kinase phosphorylation. Neuropharmacology (2015) 0.78
Degree of myelination (g-ratio) of the human recurrent laryngeal nerve. Eur Arch Otorhinolaryngol (2013) 0.77
N-acetylcysteine downregulates phosphorylated p-38 expression but does not reverse the increased superoxide anion levels in the spinal cord of rats with neuropathic pain. Braz J Med Biol Res (2017) 0.75
The Role of Unfolded Protein Response and Mitogen-Activated Protein Kinase Signaling in Neurodegenerative Diseases with Special Focus on Prion Diseases. Front Aging Neurosci (2017) 0.75
P2Y2 nucleotide receptor activation enhances the aggregation and self-organization of dispersed salivary epithelial cells. Am J Physiol Cell Physiol (2014) 0.75
"Three Methods and Three Points" regulates p38 mitogen-activated protein kinase in the dorsal horn of the spinal cord in a rat model of sciatic nerve injury. Neural Regen Res (2016) 0.75
Enhancement of Peripheral Nerve Regrowth by the Purine Nucleoside Analog and Cell Cycle Inhibitor, Roscovitine. Front Cell Neurosci (2016) 0.75
RegenBase: a knowledge base of spinal cord injury biology for translational research. Database (Oxford) (2016) 0.75
Protective effects of methanolic extract of Juglans regia L. leaf on streptozotocin-induced diabetic peripheral neuropathy in rats. BMC Complement Altern Med (2017) 0.75
A small molecule screen identifies in vivo modulators of peripheral nerve regeneration in zebrafish. PLoS One (2017) 0.75
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1995) 11.89
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett (1995) 9.62
Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol (1999) 5.93
A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat Cell Biol (2000) 5.46
Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell (2000) 3.54
The search for physiological substrates of MAP and SAP kinases in mammalian cells. Trends Cell Biol (1997) 3.26
Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis. Proc Natl Acad Sci U S A (2000) 2.83
An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci U S A (2003) 2.75
Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature (1988) 2.47
The cytokine network of Wallerian degeneration: tumor necrosis factor-alpha, interleukin-1alpha, and interleukin-1beta. J Neurosci (2002) 2.06
Tumour necrosis factor-alpha induces ectopic activity in nociceptive primary afferent fibres. Neuroscience (1997) 2.00
Complementation of placental defects and embryonic lethality by trophoblast-specific lentiviral gene transfer. Nat Biotechnol (2007) 1.94
Interleukin-1beta promotes repair of the CNS. J Neurosci (2001) 1.92
Degeneration and regeneration of the peripheral nervous system: from Augustus Waller's observations to neuroinflammation. J Peripher Nerv Syst (2002) 1.73
Functional indices for sciatic, peroneal, and posterior tibial nerve lesions in the mouse. Microsurgery (1998) 1.60
Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience (1996) 1.52
Inflammatory cytokines IL-1 alpha, IL-1 beta, IL-6, and TNF-alpha impart neuroprotection to an excitotoxin through distinct pathways. J Immunol (1999) 1.45
Catalytic activation of mitogen-activated protein (MAP) kinase phosphatase-1 by binding to p38 MAP kinase: critical role of the p38 C-terminal domain in its negative regulation. Biochem J (2000) 1.35
p38 MAPK signalling cascades: ancient roles and new functions. Bioessays (2000) 1.25
Wallerian degeneration after crush injury of rat sciatic nerve increases endo- and epineurial tumor necrosis factor-alpha protein. Neurosci Lett (2004) 1.14
Inhibition of p38 MAP kinase activity enhances axonal regeneration. Exp Neurol (2003) 1.13
Interfering with MAP kinase docking interactions: implications and perspective for the p38 route. Cell Cycle (2007) 1.07
Expression of cytotactin in the normal and regenerating neuromuscular system. J Cell Biol (1989) 1.04
Interleukin-1 beta protects neurons via the interleukin-1 (IL-1) receptor-mediated Akt pathway and by IL-1 receptor-independent decrease of transmembrane currents in vivo. Mol Cell Neurosci (2003) 1.03
Enhanced expression of the extracellular matrix molecule J1/tenascin in the regenerating adult mouse sciatic nerve. J Neurocytol (1990) 0.99
p38 map kinase regulates TNF-alpha production in human astrocytes and microglia by multiple mechanisms. Cytokine (2000) 0.99
Interleukin-1 beta promotes sensory nerve regeneration after sciatic nerve injury. Neurosci Lett (2008) 0.99
Macrophages are eliminated from the injured peripheral nerve via local apoptosis and circulation to regional lymph nodes and the spleen. J Neurosci (2001) 0.98
Tumor necrosis factor receptor 1 and 2 proteins are differentially regulated during Wallerian degeneration of mouse sciatic nerve. Exp Neurol (2005) 0.97
Adult Rat Dorsal Root Ganglion Neurons Extend Neurites on Predegenerated But Not on Normal Peripheral Nerves In Vitro. Eur J Neurosci (1992) 0.91
Interleukin-1 beta and interferon-gamma induce proliferation and apoptosis in cultured Schwann cells. J Neuroimmunol (2002) 0.89
Induction of apoptosis signal regulating kinase 1 (ASK1) after spinal cord injury in rats: possible involvement of ASK1-JNK and -p38 pathways in neuronal apoptosis. J Neuropathol Exp Neurol (1999) 0.87
Expression of activating transcription factor 3 (ATF 3) and caspase 3 in Schwann cells and axonal outgrowth after sciatic nerve repair in diabetic BB rats. Neurosci Lett (2012) 0.87
Pathomechanism of entrapment neuropathy in diabetic and nondiabetic rats reared in wire cages. Histol Histopathol (2008) 0.86
Nonviral HVJ (hemagglutinating virus of Japan) liposome-mediated retrograde gene transfer of human hepatocyte growth factor into rat nervous system promotes functional and histological recovery of the crushed nerve. Neurosci Res (2005) 0.85
Spatiotemporal quantification of tumor necrosis factor-alpha and interleukin-10 after crush injury in rat sciatic nerve utilizing immunohistochemistry. Neurosci Lett (2007) 0.83
Efficient gene transfer from innervated muscle into rat peripheral and central nervous systems using a non-viral haemagglutinating virus of Japan (HVJ)-liposome method. J Neurochem (2003) 0.80
Regeneration of the perineurium after microsurgical resection examined with immunolabeling for tenascin-C and alpha smooth muscle actin. J Anat (2011) 0.80
Changes in the concentration of enolase isozymes and S-100 protein in degenerating and regenerating rat sciatic nerve. J Neurochem (1983) 0.79
Tenascin-C expression during wallerian degeneration in C57BL/Wlds mice: possible implications for axonal regeneration. J Neurocytol (1995) 0.78
Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol (2002) 5.41
RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature (2002) 4.44
Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res (2003) 2.73
Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J (2003) 2.30
Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem (2004) 2.29
Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. J Bone Miner Res (2013) 2.25
Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity (2008) 2.16
Bril: a novel bone-specific modulator of mineralization. J Bone Miner Res (2008) 2.11
Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One (2011) 2.10
Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J Neurosci (2004) 2.04
Complementation of placental defects and embryonic lethality by trophoblast-specific lentiviral gene transfer. Nat Biotechnol (2007) 1.94
Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem (2008) 1.88
Ras-ERK MAPK cascade regulates GATA3 stability and Th2 differentiation through ubiquitin-proteasome pathway. J Biol Chem (2005) 1.72
Essential role for ERK2 mitogen-activated protein kinase in placental development. Genes Cells (2003) 1.71
Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by {gamma}-carboxylation-dependent and -independent mechanisms. Am J Physiol Cell Physiol (2009) 1.64
Patched1 haploinsufficiency increases adult bone mass and modulates Gli3 repressor activity. Dev Cell (2008) 1.54
Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone (2007) 1.52
Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling. Arthritis Res Ther (2007) 1.47
RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res (2003) 1.46
BDNF induction with mild exercise in the rat hippocampus. Biochem Biophys Res Commun (2007) 1.39
TWEAK is a novel arthritogenic mediator. J Immunol (2006) 1.37
Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res (2009) 1.36
RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res (2006) 1.33
Follicle-stimulating hormone activates extracellular signal-regulated kinase but not extracellular signal-regulated kinase kinase through a 100-kDa phosphotyrosine phosphatase. J Biol Chem (2002) 1.27
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol (2005) 1.26
BANK negatively regulates Akt activation and subsequent B cell responses. Immunity (2006) 1.21
Dynamic changes in the mobility of LAT in aggregated lipid rafts upon T cell activation. J Cell Biol (2003) 1.19
Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res (2011) 1.19
Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res (2009) 1.18
Progression of acetabular periprosthetic osteolytic lesions measured with computed tomography. J Bone Joint Surg Am (2007) 1.16
Metabolic and endocrine consequences of social stress in a visible burrow system. Physiol Behav (2004) 1.14
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer (2002) 1.11
Inhibitory effects of an orexin-2 receptor antagonist on orexin A- and stress-induced ACTH responses in conscious rats. Neurosci Res (2006) 1.11
Erk pathways negatively regulate matrix mineralization. Bone (2006) 1.08
Identification of IFN regulatory factor-1 binding site in IL-12 p40 gene promoter. J Immunol (2003) 1.07
The proliferation and phenotypic expression of human osteoblasts on tantalum metal. Biomaterials (2004) 1.07
The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone (2004) 1.06
A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Commun (2008) 1.05
Biomechanical properties of porcine flexor tendon fixation with varying throws and stitch methods. Am J Sports Med (2012) 1.05
CRFR1 is expressed on pancreatic beta cells, promotes beta cell proliferation, and potentiates insulin secretion in a glucose-dependent manner. Proc Natl Acad Sci U S A (2009) 1.04
Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption. Endocrinology (2010) 1.04
Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL. J Exp Med (2003) 1.04
Autoimmunity to the sodium-level sensor in the brain causes essential hypernatremia. Neuron (2010) 1.03
Biocompatible polymer coating of titania nanotube arrays for improved drug elution and osteoblast adhesion. Acta Biomater (2011) 1.02
The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials (2009) 1.01
The use of OP-1 in femoral impaction grafting in a sheep model. J Orthop Res (2004) 1.01
Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer. Mol Cancer Ther (2009) 1.00
The skeleton as an intracrine organ for vitamin D metabolism. Mol Aspects Med (2008) 0.99
Development of a patient-specific simulator for laparoscopic renal surgery. Int J Urol (2012) 0.99
Regulation of osteoclast apoptosis and motility by small GTPase binding protein Rac1. J Bone Miner Res (2005) 0.98
Suppression of arthritic bone destruction by adenovirus-mediated dominant-negative Ras gene transfer to synoviocytes and osteoclasts. Arthritis Rheum (2003) 0.97
Primary human osteoblasts grow into porous tantalum and maintain an osteoblastic phenotype. J Biomed Mater Res A (2008) 0.97
Signal transduction pathways regulating osteoclast differentiation and function. J Bone Miner Metab (2003) 0.97
Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone (2004) 0.97
The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). J Bone Miner Res (2004) 0.96
Brain glycogen supercompensation following exhaustive exercise. J Physiol (2011) 0.96
Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther (2009) 0.96
Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. J Bone Miner Res (2002) 0.96
Consensus substrate sequence for protein-tyrosine phosphatase receptor type Z. J Biol Chem (2011) 0.95
Transcriptional coactivator PC4 stimulates promoter escape and facilitates transcriptional synergy by GAL4-VP16. Mol Cell Biol (2004) 0.95
Osteoblast-chondrocyte interactions in osteoarthritis. Curr Osteoporos Rep (2014) 0.95
Threshold-like pattern of neuronal activation in the hypothalamus during treadmill running: establishment of a minimum running stress (MRS) rat model. Neurosci Res (2007) 0.94
IL-1 regulates cytoskeletal organization in osteoclasts via TNF receptor-associated factor 6/c-Src complex. J Immunol (2002) 0.94
The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. Biomaterials (2006) 0.93
The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions. J Bone Miner Metab (2008) 0.93
Canonical Wnts and BMPs cooperatively induce osteoblastic differentiation through a GSK3beta-dependent and beta-catenin-independent mechanism. Differentiation (2010) 0.93
Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin Cancer Res (2009) 0.93
Identification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding. J Biol Chem (2005) 0.92
Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J Bone Miner Res (2008) 0.92
Regulation of bone mass by mechanical loading: microarchitecture and genetics. Curr Osteoporos Rep (2005) 0.92
Encapsulation of chondrocytes in photopolymerizable styrenated gelatin for cartilage tissue engineering. Tissue Eng (2006) 0.92
MAPK1 is required for establishing the pattern of cell proliferation and for cell survival during lens development. Development (2013) 0.91
Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells. J Immunol (2009) 0.91
A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H. Biochem Biophys Res Commun (2011) 0.90
Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J Bone Miner Res (2011) 0.90
PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts. Blood (2008) 0.90
Screening for vitamin D deficiency. Ann Intern Med (2015) 0.90
Protein tyrosine phosphatase receptor type z negatively regulates oligodendrocyte differentiation and myelination. PLoS One (2012) 0.89
Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. J Cell Physiol (2005) 0.89
Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis. Mod Rheumatol (2007) 0.88
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer (2006) 0.88